PRESS RELEASE

Heidelberg Pharma to present its proprietary ATAC technology platform at the AACR Annual Meeting 2019

Ladenburg, Germany, 27 March 2019 - Heidelberg Pharma AG (FSE: WL6) announced today that it will present preclinical data on the application of its proprietary ATAC technology platform in the treatment of triple-negative breast cancer at the Annual Meeting of the American Association for Cancer Research (AACR) 2019.

AACR Annual Meeting 2019
Date: 29 March - 3 April
Venue: Georgia World Congress Center, Atlanta, USA

Details of the presentation:
Preclinical evaluation of anti-HER2 Antibody Targeted Amanitin Conjugates (ATACs) on HER2low breast cancer with chromosome 17p deletion
Abstract number: 237, Section 9
Presenter: Dr. Christian Breunig
Date: 31 March 2019, 1.00 pm - 5.00 pm EDT

In a poster presentation, Heidelberg Pharma will present preclinical data on an ATAC that is aimed against the breast cancer antigen HER2. This ATAC has the potential to efficiently target tumors with low HER2 expression, which are frequent in triple negative breast cancer. Further, the data show that aggressive tumors with a 17p deletion are particularly susceptible to this treatment.

The abstract of the presentation is available on the website of the AACR: https://www.abstractsonline.com/pp8/#!/6812/presentation/2954.

The corresponding poster can be found at the Company's website under "Press & Investors > Calendar and Presentations > Scientific posters" from 31 March 2019.

About Heidelberg Pharma's proprietary ATAC technology

Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON^(R) and REDECTANE^(R), while RENCAREX^(R) is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.